High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia

Cancer Science

Volumn 104, Issue 8, 2013, Pages 996-1001

  Fang, Cheng ^a   Zhuang, Yun ^b   Wang, Li ^a   Fan, Lei ^a   Wu, Yu Jie ^a   Zhang, Run ^a   Zou, Zhi Jian ^a   Zhang, Li Na ^a   Yang, Shu ^a   Xu, Wei ^a   Li, Jian Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHINESE; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MALE; MEAN FLUORESCENCE INTENSITY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84881094187     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12192     Document Type: Article

References (21)

1. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, Group EGW. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 (Suppl. 6): vi50-4.
2. Hamblin TJ. Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia. Leuk Res 2011; 35: 1432-5.
3. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
4. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118: 3470-8.
5. Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
6. Tam CS, Otero-Palacios J, Abruzzo LV et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008; 141: 36-40.
7. Hsi ED, Kopecky KJ, Appelbaum FR et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2003; 120: 1017-25.
8. Borowitz MJ, Shuster J, Carroll AJ et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study. Blood 1997; 89: 3960-6.
9. Jeha S, Behm F, Pei D et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2006; 108: 3302-4.
10. Maury S, Huguet F, Leguay T et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 2010; 95: 324-8.
11. Thomas DA, O'Brien S, Jorgensen JL et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009; 113: 6330-7.
12. Suzuki Y, Yoshida T, Wang G et al. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Ann Hematol 2012; 91: 997-1005.
13. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-56.
14. Xu W, Li JY, Wu YJ et al. CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009; 33: 237-43.
15. Xu W, Li JY, Wu YJ et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008; 32: 1071-7.
16. Chen L, Zhang Y, Zheng W et al. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008; 32: 1491-8.
17. Sarro SM, Unruh TL, Zuccolo J et al. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. Leuk Res 2010; 34: 1670-3.
18. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364-9.
19. Musto P, D'Auria F. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. Expert Opin Biol Ther 2011; 11: 551-7.
20. SH S, E C, NL H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon, France: IARC Press, 2008.
21. Johnson NA, Boyle M, Bashashati A et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009; 113: 3773-80.